All News

RheumNow Podcast square

National Population Insights (4.28.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article
computer screen safety

RA Patients on Biologics and tsDMARDs are still High Risk

Jack Cush, MD

A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.

Read Article
warning, caution

EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks

Jack Cush, MD

The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.

Read Article
RheumNow Podcast square

Night Splinting for Carpal Tunnel (3.24.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com.  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

Read Article
Dr. Stanley Cohen on JAKinibs: Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions @RheumNow #RNL2023 https://t.co/ulLh2HikUt https://t.co/0kR8CNZvsV

Links:

Dr. John Cush RheumNow ( View Tweet)
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV

Links:

Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/wfrlAcij8x https://t.co/OvqKrHw5Wu

Links:

Dr. John Cush RheumNow ( View Tweet)
The European Commission has approved upadacitinib (Rinvoq) for the Treatment of Moderately to Severely Active Crohn's Disease https://t.co/Clzca7jU5b https://t.co/nNFGe5fF25

Links:

Dr. John Cush RheumNow ( View Tweet)
RA Patients on Biologics and tsDMARDs are still High Risk A new Swedish ARTIS registry study of key safety outcomes in RA patients receiving either targeted synthetic or b/ts DMARDs, including JAKi, has been updated and affirms previously held risks. https://t.co/mqfP4deGJv https://t.co/m43GSRlrct

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks https://t.co/rMEqodKdVN https://t.co/OT0gRRADIc

Links:

Dr. John Cush RheumNow ( View Tweet)
The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu . https://t.co/nzuHh6v0ua

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center study of 320 Difficult to Rx RA (D2TRA) pts, found 76 EULAR-D2TRA pts (24%). D2TRA more likely to be lower socio-economic, RF+, have ILD, higher DAS28-CRP and were more likely to respond to rituximab and JAK inhibitors https://t.co/aEvP6WDvQu https://t.co/FQJvo81FbM

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/Ej0Rm2VFCk https://t.co/aiHGE1LsAr

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Eric Ruderman with an excellent review of the JAK/STAT pathway especially for PsA treatment @RheumNow #RNL2023 https://t.co/kNDouZ4kCV
Robert B Chao, MD doctorRBC ( View Tweet)
TYK2 in plaque psoriasis By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Safer? No lab monitoring And it works https://t.co/9Woen2q4hZ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
TYK2 signalling Vs JAK signalling summary #RNL2023 https://t.co/0VNBiEc6jq
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Why JAKinibs in PsA ?! By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Also inflammatory bowel disease and most recently Upadacitinib for crohns disease. https://t.co/loUgJNUsKT
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Jaks are every where in Psoriatic disease domains, By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Good news, especially with Updacitinib recently and Crohn’s disease ( full package). https://t.co/nlBWJhzpLp
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
@RheumNow Live #RNL2023 Stanley Cohen, MD: Use of JAK inhibitor in patients with known ASCVD: Number needed to harm 16 ASCVD is biggest risk factor for MACE events with JAKi https://t.co/gXNUOO8seG
Eric Dein ericdeinmd ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×